ProKidney (PROK) AI Stock Analysis

• Market Cap: $304.84M
• Dividend Yield: N/A
• Average Volume (3M): 497.94K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.32
• Revenue Growth: N/A
• EPS Growth: 4.19%
• Country: US
• Employees: 163
• Sector: Healthcare
• Sector Strength: 78
• Industry: Biotechnology
• EPS (TTM): -0.56
• Shares Outstanding: 127,968,250
• 10 Day Avg. Volume: 774,604
• 30 Day Avg. Volume: 497,939
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -2.60
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $3.00
• Price Target Upside: 188.46% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

ProKidney's overall stock score is significantly impacted by its weak financial performance, marked by ongoing losses and negative equity, which are critical risks. The technical analysis suggests a bearish trend, further weighing on the score. Valuation metrics, particularly the negative P/E ratio, reflect the company's financial struggles. The lack of notable earnings call insights or corporate events results in a largely neutral impact from those factors.

Positive Factors

Market Potential

Rilparencel is a differentiated approach in diabetic CKD with blockbuster potential.

Regulatory Approval

FDA confirmed that PROACT 1 could be sufficient to support a BLA submission and full approval.

Negative Factors

Financial Performance

Topline results for the PROACT 1 study are expected in 3Q27, beyond the company's current cash runway.

ProKidney Business Overview & Revenue Model

Company Description

ProKidney (PROK) is a healthcare company specializing in the research and development of innovative treatments for chronic kidney disease (CKD). The company focuses on leveraging advanced biotechnological approaches to regenerate kidney function and improve patient outcomes. ProKidney operates within the biopharmaceutical sector and aims to provide cutting-edge therapies to address the unmet medical needs of CKD patients.

How the Company Makes Money

ProKidney makes money primarily through the development and commercialization of its proprietary therapies for chronic kidney disease. The company's revenue model centers on the successful progression of its treatments through clinical trials and obtaining regulatory approvals. Key revenue streams include potential licensing agreements, partnerships with other pharmaceutical companies, and eventual sales of approved therapies. Additionally, ProKidney may receive funding from grants, research collaborations, and investment from venture capital to support its research and development activities.

ProKidney Financial Statement Overview

Summary

ProKidney faces significant financial challenges, primarily due to ongoing losses and negative equity. The company has started to generate revenue, but profitability and operational efficiency remain major hurdles. Cash reserves provide some short-term relief, but improving revenue growth and managing costs are critical for long-term viability.

Income Statement

ProKidney's income statement reveals significant challenges. The company has experienced substantial net losses over multiple periods, with a negative net profit margin due to consistent negative net income. The gross profit margin is not applicable due to minimal or negative revenue in prior years, and the company has only recently started generating revenue. The EBIT and EBITDA margins are deeply negative, indicating operational inefficiencies and high costs relative to revenue.

Balance Sheet

The balance sheet shows a precarious position with negative stockholders' equity, indicating insolvency risk. The debt-to-equity ratio is not meaningful due to negative equity, and the equity ratio is also negative. Total liabilities are relatively low, but the high negative equity suggests financial instability. The company has a high cash balance, which provides some liquidity, but overall financial health appears weak.

Cash Flow

ProKidney's cash flow statement highlights substantial negative operating cash flow, indicating operational struggles. The free cash flow is also negative, exacerbating concerns about liquidity and sustainability. While there is some positive cash flow from financing activities, it is not sufficient to cover operational deficits in the long term. The company needs to improve cash generation from its core operations.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
4.49M	0.00	0.00	0.00	0.00	0.00
	Gross Profit
1.67M	-3.17M	-3.04M	-1.98M	0.00	0.00
	EBIT
-156.31M	-151.52M	-153.01M	-55.11M	-27.02M	-19.16M
	EBITDA
-132.02M	-147.67M	-143.99M	-53.13M	-26.02M	-18.29M
	Net Income Common Stockholders
-45.61M	-35.47M	-148.13M	-55.15M	-26.75M	-79.61M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
362.95M	362.95M	490.25M	20.56M	4.58M	15.23M
	Total Assets
420.55M	420.55M	518.00M	40.30M	16.70M	19.61M
	Total Debt
4.41M	4.41M	2.40M	1.33M	1.56M	1.01M
	Net Debt
-56.24M	-56.24M	-487.85M	-19.22M	-3.02M	-14.22M
	Total Liabilities
29.22M	29.22M	13.06M	13.38M	6.84M	3.72M
	Stockholders Equity
-1.10B	-1.10B	-1.10B	26.92M	9.86M	15.88M
Cash Flow		Free Cash Flow
-129.14M	-124.27M	-78.94M	-55.49M	-30.64M	-78.11K
	Operating Cash Flow
-127.56M	-90.07M	-77.09M	-50.30M	-25.18M	-76.81K
	Investing Cash Flow
-90.51M	-329.98M	-1.74M	-5.19M	-5.46M	-2.97K
	Financing Cash Flow
134.77M	-9.55M	548.52M	71.47M	19.99M	20.00K

ProKidney Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.04
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PROK, the sentiment is Negative. The current price of 1.04 is below the 20-day moving average (MA) of 1.35, below the 50-day MA of 1.55, and below the 200-day MA of 2.06, indicating a bearish trend. The MACD of -0.16 indicates Positive momentum. The RSI at 21.22 is Positive, neither overbought nor oversold. The STOCH value of 10.47 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PROK.

ProKidney Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MIRM	54 Neutral	$2.16B	―	-37.08%	―	80.76%	53.98%
Sector *	49 Neutral	$6.90B	0.02	-54.05%	2.46%	24.91%	-3.14%
CRSP	46 Neutral	$3.63B	―	-19.20%	―	-89.95%	-123.71%
FATE	42 Neutral	$110.00M	―	-54.21%	―	-78.55%	-0.92%
PROK	35 Underperform	$304.84M	―	4.66%	―	―	4.19%
RCKT	32 Underperform	$875.43M	―	-54.14%	―	―	6.99%
ALLK	27 Underperform	$22.84M	―	-121.68%	―	―	-5.32%